Intravitreal versus subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular oedema

ISRCTN ISRCTN67086909
DOI https://doi.org/10.1186/ISRCTN67086909
Secondary identifying numbers N/A
Submission date
05/02/2008
Registration date
20/02/2008
Last edited
15/04/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Mauro Cellini
Scientific

Via Massarenti, 9
Bologna
40100
Italy

Study information

Study designAn interventional randomised double-blind study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study objectivesMacular oedema is the main cause of loss of visual acuity in diabetic patients. It may occur at any stage of the retinal disorder and is the most common cause of sight reductions in these subjects.

In the oedema, the haemato-retinal barrier is damaged by an alteration in the tight junction between the retinal capillary endothelial cells and the pigmented epithelial cells with the consequent leakage of water and electrolytes in the retinal tissue.

The use of corticosteroids for the treatment of retinal oedema is linked to their capacity to inhibit the initial arachidonic acid cascade, to determine a down-regulation of the cytokines and to attenuate the tearing of the haemato-retinal barrier.

Hypothesis:
To assess the efficacy of the intravitreal (IVT) injection of triamcinolone acetonide (TA) as compared to posterior subtenon (SBT) capsule injection for the treatment of cystoid diabetic macular oedema.
Ethics approval(s)Ethics approval received from the Institutional Ethics Committee of the S. Orsola-Malpighi Hospital on the 12th September 2006 (ref: OFC06-01).
Health condition(s) or problem(s) studiedMacular oedema
InterventionFor the IVT injection, the patient was placed supine and we performed a surface anaesthesia with topical 4% carbocaine followed by a preparation with 5% povidone iodine. A volume of 0.1 ml containing 4 mg preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) was injected through the inferotemporal pars-plana (4.0 mm posterior to the limbus) using a 30-gauge needle.

For the SBT injection, the patient was placed supine and after topical 0.4% oxybuprocaine surface anaesthesia we administered 0.5 ml of a 40 mg/ml peribulbar inferotemporal subtenon injection of preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) with a 27-gauge needle.

The follow-up was of 6 months for all treatment arms.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Triamcinolone acetonide
Primary outcome measureVisual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, measured every month until the end of follow-up.
Secondary outcome measuresMacular thickness was measured by optical coherence tomography (OCT), measured every month until the end of follow-up.
Overall study start date03/02/2004
Completion date18/10/2004

Eligibility

Participant type(s)Patient
Age groupSenior
SexBoth
Target number of participants28
Key inclusion criteria1. Patients aged between 61 and 74 years (mean 68.3), either sex
2. With type II diabetes mellitus
3. On insulin treatment
4. Presenting diffuse macular oedema without retinal-vitreous traction
Key exclusion criteria1. History of focal/grid laser photocoagulation in the macula
2. Record of uveitis episodes
3. Previous ocular surgery, glaucoma and ocular hypertension
Date of first enrolment03/02/2004
Date of final enrolment18/10/2004

Locations

Countries of recruitment

  • Italy

Study participating centre

Via Massarenti, 9
Bologna
40100
Italy

Sponsor information

St Orsola Malpighi University Hospital Bologna (Italy)
University/education

Ophthalmology Service
Department of Surgery and Transplant
via Massarenti, 9
Bologna
40138
Italy

ROR logo "ROR" https://ror.org/00t4vnv68

Funders

Funder type

Hospital/treatment centre

St Orsola Malpighi University Hospital Bologna (Italy)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 17/03/2008 Yes No